The RAS signaling pathway is one of the most commonly dysregulated pathways in urological cancers. This pathway can be regulated by RASGAPs, which catalyze the hydrolysis of RAS-GTP to RAS-GDP. As such, the loss of RASGAPs can promote the activation of the RAS signaling pathway. Dysregulation of RASGAPs significantly contributes to the progression of urological cancers, including prostate cancer, bladder cancer, and renal cell carcinoma. Furthermore, alterations in RASGAP expression may influence sensitivity to chemotherapy, radiotherapy, and targeted therapies, suggesting their potential as therapeutic targets. Despite the challenges involved, a deeper understanding of the complexity of the RAS signaling network, along with the evolution of personalized medicine, holds promise for delivering more precise and effective treatment options targeting RASGAPs in urological cancers.
RAS信号通路是泌尿系统肿瘤中最常失调的通路之一。该通路受RASGAPs调控，后者催化RAS-GTP水解为RAS-GDP。因此，RASGAPs的缺失会促进RAS信号通路的激活。RASGAPs的失调显著推动前列腺癌、膀胱癌和肾细胞癌等泌尿系统肿瘤的进展。此外，RASGAP表达的改变可能影响对化疗、放疗及靶向治疗的敏感性，提示其作为治疗靶点的潜力。尽管面临诸多挑战，但随着对RAS信号网络复杂性的深入理解以及个体化医疗的发展，针对泌尿系统肿瘤中RASGAPs开发更精准有效的治疗方案前景可期。
肿瘤(癌症)患者之家